NCT06856174 - Menopausal HT for Women Living With HIV (HoT) | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

January 19, 2026

Primary Completion Date

September 20, 2027

Study Completion Date

September 20, 2027

Conditions

HIV InfectionMenopause

Interventions

DRUG

Transdermal estradiol gel

All participants: Estradiol gel 0.1%, 0.75 grams (corresponding to estradiol 0.75 mg) applied to the skin of the upper thigh once daily for 12 weeks.

DRUG

Micronized Progesterone

Participants with intact uterus: Encapsulated micronized progesterone 100 mg orally once daily for 12 weeks.

DRUG

Placebo for estradiol gel

All participants: Placebo for estradiol gel 0.1%, 0.75 grams applied to the skin of the upper thigh once daily for 12 weeks.

DRUG

Placebo for micronized progesterone

• Participants with intact uterus: Encapsulated placebo for micronized progesterone 100 mg orally once daily for 12 weeks.